ArticleNature medicine2024

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Karim Fizazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.